A discrete choice experiment on preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: the identification, refinement and selection of attributes and levels

A discrete choice experiment on preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: the identification, refinement and selection of attributes and levels

Elke GE Mathijssen,1 Milou van Heuckelum,2 Liset van Dijk,3 Marcia Vervloet,3 Simone MT Zonnenberg,1 Johanna E Vriezekolk,1 Bart JF van den Bemt2 1Department of Rheumatology, Sint Maartenskliniek, Nijmegen, the Netherlands; 2Department of Rheumatology and Pharmacy, Sint Maartenskliniek, Nijmegen, t...

Full description

Bibliographic Details
Main Authors:	Mathijssen EGE, van Heuckelum M, van Dijk L, Vervloet M, Zonnenberg SMT, Vriezekolk JE, van den Bemt BJF
Format:	Article
Language:	English
Published:	Dove Medical Press 2018-08-01
Series:	Patient Preference and Adherence
Subjects:	Discrete choice experiment mixed-methods patient preferences rheumatoid arthritis disease-modifying antirheumatic drugs
Online Access:	https://www.dovepress.com/a-discrete-choice-experiment-on-preferences-of-patients-with-rheumatoi-peer-reviewed-article-PPA

Similar Items

Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment
by: van Heuckelum M, et al.
Published: (2019-07-01)

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
by: Xia Y, et al.
Published: (2016-05-01)

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
by: Yinzhu Jin, et al.
Published: (2017-07-01)

Lipid profiles in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs
by: Anna Filipowicz-Sosnowska, et al.
Published: (2014-06-01)

Recent evidence comparing combination of conventional synthetic disease-modifying antirheumatic drugs with biologic disease-modifying antirheumatic drugs in rheumatoid arthritis
by: Abhishek Zanwar, et al.
Published: (2017-01-01)

Support needs for medication use and the suitability of eHealth technologies to address these needs: a focus group study of older patients with rheumatoid arthritis
by: Mathijssen EGE, et al.
Published: (2018-03-01)

Conventional synthetic disease-modifying antirheumatic drug use by race/ethnicity and factors associated with initiating biologics in Malaysian patients with rheumatoid arthritis
by: Suad Mohammed, et al.
Published: (2019-01-01)

The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis
by: Yu. V. Muravyev, et al.
Published: (2018-09-01)

Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
by: Yu. V. Muraviev, et al.
Published: (2018-12-01)

Effect of disease-modifying antirheumatic drug therapy on immune response to trivalent influenza vaccine in rheumatoid arthritis
by: Vikramraj K Jain, et al.
Published: (2017-01-01)

Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis
by: Sofie Bliddal, et al.
Published: (2017-07-01)

Factors associated with the initiation of biologic disease modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis
by: Kim, Gilwan
Published: (2014)

Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study
by: Motomu Hashimoto, et al.
Published: (2018-08-01)

Development of an antirheumatic drug
by: Voyi, Kuku Vinolia Vuyelwa
Published: (2016)

Use of tofacitinib in real clinical practice to treat patients with rheumatoid arthritis resistant to synthetic and biological disease-modifying antirheumatic drugs: Results of a multicenter observational study
by: D. E. Karateev, et al.
Published: (2016-09-01)

Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians
by: Emma Sullivan, et al.
Published: (2020-04-01)

Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
by: Kemper Alex R, et al.
Published: (2012-03-01)

Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry
by: Philip J. Mease, et al.
Published: (2021-09-01)

Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
by: Ko-Jen Li, et al.
Published: (2021-07-01)

Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region
by: Zoltán Kaló, et al.
Published: (2017-01-01)

Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan
by: Emma Sullivan, et al.
Published: (2020-05-01)

Effect of immunomodulating treatment (usage of DMARDs) in rheumatoid arthritis on depression
by: Magdalena Kozyra, et al.
Published: (2020-08-01)

Simplified disease activity changes in real-world practice: a nationwide observational study of seropositive rheumatoid arthritis patients with moderate-to-high disease activity
by: Kichul Shin, et al.
Published: (2020-01-01)

Cost-minimization analysis of subcutaneous abatacept in the treatment of rheumatoid arthritis in Spain
by: R. Ariza, et al.
Published: (2014-07-01)

Differential long-term retention of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis by age group from the FIRST registry
by: Akio Kawabe, et al.
Published: (2020-06-01)

GLUCOCORTICOIDS AND RHEUMATOID ARTHRITIS
by: Zhdan V. M., et al.
Published: (2020-12-01)

Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled
by: Shin-ya Kawashiri, et al.
Published: (2017-05-01)

A comparative study of total knee arthroplasty outcome for stiff knee with or without sequential antirheumatic drug treatment
by: Cheng-Qi Jia, et al.
Published: (2021-08-01)

The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus
by: Eun-Jung Park, et al.
Published: (2020-01-01)

Persistence of biological agents over an eight-year period in rheumatoid arthritis and spondyloarthritis patients
by: María Ángeles González-Fernández, et al.
Published: (2019-01-01)

MODERN VIEWS ON PATHOGENETIC THERAPY OF RHEUMATOID ARTHRITIS
by: D. G. Rekalov, et al.
Published: (2013-12-01)

Prospects for rheumatoid arthritis pharmacotherapy: New opportunities and recommendations
by: E L Nasonov
Published: (2016-12-01)

End-stage rheumatoid arthritis: specific features of patient management
by: Nadezhda Aleksandrovna Shostak, et al.
Published: (2013-06-01)

Tofacitinib in the treatment of active rheumatoid arthritis – single-centre experience
by: Marta Madej, et al.
Published: (2019-08-01)

Early rheumatoid arthritis therapy: comparative characteristic of delagil, sulphasalazine and methotrexate
by: T S Salnikova, et al.
Published: (2003-08-01)

The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
by: Natalia Vladimirovna Chichasova
Published: (2014-12-01)

Disease-modifying antirheumatic drugs – Old and new: A brief overview
by: Vidya Divakar Baliga, et al.
Published: (2019-01-01)

Rheumatoid arthritis: problems of treatment at the present stage
by: N. V. Chichasova
Published: (2018-12-01)

STRATEGY FOR DOSE REDUCTION AND DISCONTINUATION OF BIOLOGICAL AGENTS IN RHEUMATOID ARTHRITIS REMISSION
by: M. A. Kotovskaya, et al.
Published: (2018-03-01)

Impact of Rheumatoid Arthritis on Alopecia: A Nationwide Population-Based Cohort Study in Taiwan
by: Yi-Jung Chang, et al.
Published: (2020-04-01)